David Nathanson

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

Özlem Erdogdu, David Nathanson, Åke Sjöholm et al. · Molecular and Cellular Endocrinology · 2010 · 223 citations

Inflammation, Signal Transduction, Molecular Physiology +13

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( <scp>CVD‐REAL Nordic</scp> ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: <scp>A</scp> multinational observational study

Frederik Persson, Thomas Nyström, Marit E. Jørgensen et al. · Diabetes Obesity and Metabolism · 2017 · 214 citations · Full text

Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality

Jan W. Eriksson, Johan Bodegård, David Nathanson et al. · Diabetes Research and Clinical Practice · 2016 · 86 citations · Full text

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

Thomas Nyström, Johan Bodegård, David Nathanson et al. · Diabetes Obesity and Metabolism · 2017 · 84 citations · Full text

Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin

Grażyna Lietzau, William Davidsson, Claes‐Göran Östenson et al. · Acta Neuropathologica Communications · 2018 · 57 citations · Full text